Nasdaq:US$18.16 (-0.83) | HKEX:HK$30.35 (+0.00) | AIM:£2.90 (-0.14)
What We Do

We are an innovative, commercial-stage biopharmaceutical company based in China, striving to create differentiated novel oncology and immunology treatments with potential to be marketed globally.

Over the past 20 years, we have established a fully integrated oncology business, from discovery and development, all the way to manufacturing to commercialization.